Drug
Bermekimab clinical trials
Also written JNJ-77474462, MABp1 and Xilonix.
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 3
Janssen Research & Development, LLC (16) · Hellenic Institute for the Study of Sepsis (1) · Andrew Hendifar, MD (1) · Evangelos J. Giamarellos-Bourboulis, M.D. (1)
Often tested with
Tested in the same studies.
Irinotecan sucrosofate (1) · Irinotecan (1) · Fluorouracil (1)
Studies
Open first, then newest update. How each study uses bermekimab is read from its arms, and is right about nine times in ten.
Testing it · 19
- A Phase II Open Label Study of Xilonix in Subjects With Pyoderma GangrenosumCompletedPhase 2Janssen Research & Development, LLCNCT01965613Written as Xilonix
- Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT01384630Written as RA-18C3
- Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.CompletedPhase 2Janssen Research & Development, LLCNCT01270945Written as CV-18C3
- Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne VulgarisCompletedPhase 2Janssen Research & Development, LLCNCT01474798Written as RA-18C3
- A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese ParticipantsWithdrawnPhase 1Janssen Research & Development, LLCNCT05252520Written as JNJ-77474462
- A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis SuppurativaTerminatedPhase 2Janssen Research & Development, LLCNCT04988308Written as Bermekimab
- A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis SuppurativaCompletedPhase 2Janssen Research & Development, LLCNCT04019041Written as bermekimab
- A Study of JNJ-77474462 in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04544813Written as JNJ-77474462
- A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic DermatitisTerminatedPhase 2Janssen Research & Development, LLCNCT04990440Written as Bermekimab
- The Benefit of Bermekimab in Patients With Systemic SclerosisCompletedPhase 2Hellenic Institute for the Study of SepsisNCT04045743Written as MABp1 (Bermekimab)
- A Study of Bermekimab in Patients With Hidradenitis SuppurativaCompletedPhase 2Janssen Research & Development, LLCNCT03512275Written as Bermekimab Monoclonal Antibody 400 mg
- A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous DosesCompletedPhase 1Janssen Research & Development, LLCNCT04544826Written as JNJ-77474462
- A Phase III Study of Xilonix in Patients With Advanced Colorectal CancerTerminatedPhase 3Janssen Research & Development, LLCNCT01767857Written as Xilonix
- A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal CancerCompletedPhase 3Janssen Research & Development, LLCNCT02138422Written as Xilonix
- A First in Man Study of MABp1 in Patients With Advanced CancersCompletedPhase 1Janssen Research & Development, LLCNCT01021072Written as MABp1
- A Pharmacokinetic Study of MABp1 in Healthy VolunteersCompletedPhase 1Janssen Research & Development, LLCNCT03047317Written as MABp1
- Study of CA-18C3 in Subjects With Advanced Hematologic MalignanciesCompletedPhase 1Janssen Research & Development, LLCNCT01260545Written as CA-18C3
- Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With CachexiaCompletedPhase 1Andrew Hendifar, MDNCT03207724Written as Xilonix plus Onivyde and 5FU
- MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMABCompletedPhase 2Evangelos J. Giamarellos-Bourboulis, M.D.NCT02643654Written as MABp1
Given in every arm · 1 — bermekimab is usual care beside what is tested
Codes
What other systems call bermekimab · ClinicalTrials.gg INT000400
- MeSH (NLM) C000604877bermekimabOne source NLM
- UNII (FDA) N6SVN735GYBERMEKIMABConfirmed FDA, NLM
- NCI Thesaurus C95708BermekimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604877 | bermekimab | One source NLM |
| UNII (FDA) | N6SVN735GY | BERMEKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C95708 | Bermekimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.